Zhang Jie, Li Chenhui, An Yu, Wang Bing, Liang Guowei
Department of Clinical Laboratory of Aerospace Center Hospital, Beijing, China.
Front Med (Lausanne). 2024 Dec 10;11:1460233. doi: 10.3389/fmed.2024.1460233. eCollection 2024.
This meta-analysis aimed to evaluate the comparative diagnostic efficacy of Syndecan-2(SDC2) and Septin-9(SEPT9) in the early detection of colorectal cancer (CRC).
We searched PubMed, Embase, Web of Science, and Cochrane Library databases to identify available publications up to October 2024. A direct head-to-head comparator analysis were performed using the random-effects model. Subgroup analyses and corresponding meta-regressions focusing on sample source, number of patients, region, study design, and methylated detection methods were conducted. Intra-group and inter-group heterogeneity were assessed by Cochrane Q and I statistics.
Eleven articles involving 1,913 CRC patients and 2,851 healthy people were included in the meta-analysis. The sensitivity of SDC2 was similar compared to SEPT9 for CRC patients (0.67 vs. 0.71, = 0.61), SDC2 has a similar specificity in comparison to SEPT9 for CRC patients (0.90 vs. 0.91, = 0.86). In subgroup analysis, stool SDC2 was similar compared to stool SEPT9 for CRC patients (sensitivity of 0.81 vs. 0.80, = 0.92; specificity of 0.93 vs. 0.91, = 0.73), plasma SDC2 was similar compared to plasma SEPT9 for CRC patients (sensitivity of 0.57 vs. 0.72, = 0.27; specificity of 0.90 vs. 0.89, = 0.89). In the subgroup analysis of clinical staging for colorectal cancer (CRC), the results indicate that there is no significant difference in sensitivity between the two markers for both early (0.7 vs. 0.67, = 0.64) and advanced (0.76 vs. 0.70, = 0.23) stages of CRC.
In our head-to-head comparison meta-analysis, it was found that SDC2 and SEPT9 have similar sensitivity and specificity in the diagnosis of colorectal cancer. However, this result may be influenced by high heterogeneity and further confirmation of this finding is needed through large-scale prospective studies.
本荟萃分析旨在评估Syndecan-2（SDC2）和Septin-9（SEPT9）在结直肠癌（CRC）早期检测中的比较诊断效能。
我们检索了PubMed、Embase、Web of Science和Cochrane图书馆数据库，以识别截至2024年10月的可用出版物。使用随机效应模型进行直接的头对头比较分析。进行了亚组分析以及针对样本来源、患者数量、地区、研究设计和甲基化检测方法的相应元回归分析。通过Cochrane Q和I统计量评估组内和组间异质性。
荟萃分析纳入了11篇文章，涉及1913例CRC患者和2851名健康人。对于CRC患者，SDC2的敏感性与SEPT9相似（0.67对0.71，P = 0.61），SDC2在CRC患者中的特异性与SEPT9相似（0.90对0.91，P = 0.86）。在亚组分析中，对于CRC患者，粪便SDC2与粪便SEPT9相似（敏感性为0.81对0.80，P = 0.92；特异性为0.93对0.91，P = 0.73），血浆SDC2与血浆SEPT9在CRC患者中相似（敏感性为0.57对0.72，P = 0.27；特异性为0.90对0.89，P = 0.89）。在结直肠癌（CRC）临床分期的亚组分析中，结果表明，在CRC的早期（0.7对0.67，P = 0.64）和晚期（0.76对0.70，P = 0.23）阶段，两种标志物的敏感性均无显著差异。
在我们的头对头比较荟萃分析中，发现SDC2和SEPT9在结直肠癌诊断中具有相似的敏感性和特异性。然而，这一结果可能受到高异质性的影响，需要通过大规模前瞻性研究进一步证实这一发现。
